Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation for its injectable SHR-A1811, marking the 10th indication for this drug [1] Group 1: Product Development - The injectable SHR-A1811 has been approved for domestic market launch in May 2025 [1] - It is indicated for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer who have HER2 activating mutations and have previously received at least one systemic therapy [1]

Core Viewpoint - The company, Anglikang, has announced its participation in the national organized procurement for the continuation of products whose agreements from batches 1-8 have expired, with several products expected to be selected for procurement [1] Group 1: Selected Products - The products proposed for selection include: - Amlodipine Besylate Tablets - Amlodipine Tablets - Aluminum Magnesium Chewable Tablets - Cefalexin Capsules - Cephalexin Capsules - Paliperidone Succinate Tablets - Ticagrelor Tablets - Theophylline Injection - Pregabalin Capsules - Levofloxacin Tablets - Cefuroxime Axetil Capsules - L-Carnitine Injection [1] Group 2: Procurement Details - The continuation procurement is based on the demand reported by medical institutions for each company's products, with the purchasing volume determined according to the selected price gradient [1] - The procurement period will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - Angli Kang (002940.SZ) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, indicating potential selection for some of its products in the upcoming procurement process [1] Group 1 - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results for the continuation of procurement on February 10, 2026 [1] - Some of the company's products are expected to be selected in this continuation procurement process [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

Core Insights - The article emphasizes the importance of tracking institutional trading activities rather than solely relying on company announcements for investment decisions [1][3][4] Group 1: Institutional Trading Insights - Institutions are actively involved in trading even when stock prices are volatile, indicating their confidence in the stock's potential [3][11] - The "institutional inventory" data serves as a key indicator of institutional participation, with sustained activity suggesting a positive outlook for the stock [3][4] - The article highlights that institutional investment logic applies across various sectors, not just popular ones, making it essential to monitor institutional activity regardless of the industry [6][9] Group 2: Investment Strategy Evolution - The shift from emotional trading to a more data-driven approach allows investors to make informed decisions based on objective metrics rather than subjective feelings [4][14] - Recognizing the absence of institutional activity in certain stocks can serve as a warning sign for potential underperformance, guiding investors away from poor choices [11][14] - The article advocates for a cognitive upgrade in investment strategies, emphasizing the use of quantitative data to minimize emotional interference and enhance decision-making processes [14]

Core Viewpoint - The company, Hunan Nanxin Pharmaceutical Co., Ltd., is planning to transfer part of its accounts receivable through public listing to optimize its asset structure, focus on core business, and enhance risk resistance [1][2]. Group 1: Strategic Initiatives - The public listing of accounts receivable aims to reduce management costs associated with receivables, allowing the company to concentrate resources on core development areas and increase investment in innovative drug research [1]. - This initiative is expected to improve the company's asset structure and operational quality by converting stagnant receivables into cash, thereby reducing the proportion of accounts receivable in total assets and transferring credit risk [1]. Group 2: Financial Implications - The transfer of accounts receivable is anticipated to enhance liquidity and security of funds, providing a quick influx of cash to alleviate pressure from capital occupation and mitigate cash flow issues caused by delayed payments [2]. - The company plans to continue optimizing its accounts receivable management system and strengthen its focus on core business and research innovation to create higher value for investors and contribute to industry development [2].

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are expected to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national organized centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement process, published by the procurement office on February 10, 2026, indicate that some of Beid Pharmaceutical's products are likely to be selected [1] - The products expected to be selected include Clarithromycin Tablets and Simvastatin Tablets, both of which are included in the national medical insurance catalog [1]

Core Viewpoint - The company announced that its subsidiaries and a holding subsidiary participated in a national procurement program and have proposed to be selected for six pharmaceutical products, with a procurement period extending until December 31, 2028 [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries, including Shaanxi Buchang High-tech Pharmaceutical Co., Ltd. and Shandong Danhong Pharmaceutical Co., Ltd., along with its holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd., are involved in the national organized procurement program [1] - The selected products include Amlodipine Besylate Tablets, Rivaroxaban Tablets, Metoprolol Tartrate Tablets, Lacosamide Tablets, Pregabalin Capsules, and Torasemide Injection [1] Group 2: Procurement Details - The procurement cycle for the selected drugs will commence from the actual execution date of the selection results and will last until December 31, 2028 [1]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the production of Tamsulosin Hydrochloride raw material by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice for the marketing application of Tamsulosin Hydrochloride [1] - Tamsulosin Hydrochloride is a third-generation highly selective long-acting α1 inhibitor, used for the treatment of benign prostatic hyperplasia [1] Group 2: Product Background - The drug was developed by Japan's Yamanouchi Pharmaceutical and was approved for marketing by the U.S. Food and Drug Administration in July 1992 [1]